{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:59:35Z","timestamp":1787313575537,"version":"build-2736575974"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    : Adult and juvenile granulosa cell tumors of the ovary are rare functional sex-cord-stromal ovarian neoplasms characterized by low malignant potential and late relapse. Evidence-based management options for primary and recurrent juvenile (JGCT) and adult (AGCT) granulosa cell tumors are limited and treatment options have not been standardized. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may be an option to treat these women effectively.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    : Systematic literature review using PubMed and the Cochrane Central Register of Controlled Trials.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : No reports of HIPEC among women with a first diagnosis of AGCT were identified. We identified 5 reports on the safety and therapeutic efficacy of CRS and HIPEC in 19 patients with recurrent AGCT and one patient with JGCT. The pooled rate of complete cytoreduction was 95\u2006% (18\/19) with 16\u2006% (3\/19) severe morbidity and no procedure-related mortality. The median time of follow-up was 30 (range, 3 to 72) months, during which 6\/19 (31\u2006%) patients experienced a recurrence and two patients (10\u2006%) died of the disease.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    : CRS and HIPEC are a safe and potentially effective treatment option for selected women with recurrent AGCT limited to the abdomen.\n                  <\/jats:p>","DOI":"10.1515\/pp-2016-0002","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T15:15:08Z","timestamp":1460560508000},"page":"15-22","source":"Crossref","is-referenced-by-count":8,"title":["Hyperthermic intraperitoneal chemotherapy for women with granulosa cell tumors of the ovary: a systematic review of the literature"],"prefix":"10.1515","volume":"1","author":[{"given":"Clemens B.","family":"Tempfer","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ruhr University Bochum, Marienhospital Herne, Hoelkeskampring 40, 44625 Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Solass","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Hannover, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Askin","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ruhr University Bochum, Marienhospital Herne, Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas A.","family":"Hefler","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Krankenhaus der Barmherzigen Schwestern, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Andr\u00e9","family":"Reymond","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"key":"2025120909190349438_j_pp-2016-0002_ref_001_w2aab3b7b9b1b6b1ab2ab1Aa","unstructured":"1. Ugianskiene A, Grove A, Soegaard-Andersen E. Adult granulosa cell tumor of the ovary: A retrospective study of 37 cases. Eur J Gynaecol Oncol 2014;35(6):621\u20134."},{"key":"2025120909190349438_j_pp-2016-0002_ref_002_w2aab3b7b9b1b6b1ab2ab2Aa","doi-asserted-by":"crossref","unstructured":"2. Bryk S, F\u00e4rkkil\u00e4 A, B\u00fctzow R, Leminen A, Heikinheimo M, Anttonen M, et al. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: A 56-year single-center experience. Int J Gynecol Cancer 2015;25(1):33\u201341.","DOI":"10.1097\/IGC.0000000000000304"},{"key":"2025120909190349438_j_pp-2016-0002_ref_003_w2aab3b7b9b1b6b1ab2ab3Aa","doi-asserted-by":"crossref","unstructured":"3. Merras-Salmio L, Vettenranta K, M\u00f6tt\u00f6nen M, Heikinheimo M. Ovarian granulosa cell tumors in childhood. Pediatr Hematol Oncol 2002;19(3):145\u201356.","DOI":"10.1080\/088800102753541297"},{"key":"2025120909190349438_j_pp-2016-0002_ref_004_w2aab3b7b9b1b6b1ab2ab4Aa","doi-asserted-by":"crossref","unstructured":"4. Kottarathil VD, Antony MA, Nair IR, Pavithran K. Recent advances in granulosa cell tumor ovary: A review. Indian J Surg Oncol 2013;4(1):37\u201347.","DOI":"10.1007\/s13193-012-0201-z"},{"key":"2025120909190349438_j_pp-2016-0002_ref_005_w2aab3b7b9b1b6b1ab2ab5Aa","doi-asserted-by":"crossref","unstructured":"5. Lee IH, Choi CH, Hong DG, Song JY, Kim YJ, Kim KT. Clinicopathologic characteristics of granulosa cell tumors of the ovary: A multicenter retrospective study. J Gynecol Oncol 2011;22:188\u201395.","DOI":"10.3802\/jgo.2011.22.3.188"},{"key":"2025120909190349438_j_pp-2016-0002_ref_006_w2aab3b7b9b1b6b1ab2ab6Aa","doi-asserted-by":"crossref","unstructured":"6. Zhang M, Cheung MK, Shin JY, Kapp DS, Husain A, Teng NN, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary: An analysis of 376 women. Gynecol Oncol 2007;104:396\u2013400.","DOI":"10.1016\/j.ygyno.2006.08.032"},{"key":"2025120909190349438_j_pp-2016-0002_ref_007_w2aab3b7b9b1b6b1ab2ab7Aa","doi-asserted-by":"crossref","unstructured":"7. Pectasides D, Pectasides E, Psyrri A. Granulosa cell tumor of the ovary. Cancer Treat Rev 2008 Feb;34(1):1\u201312.","DOI":"10.1016\/j.ctrv.2007.08.007"},{"key":"2025120909190349438_j_pp-2016-0002_ref_008_w2aab3b7b9b1b6b1ab2ab8Aa","doi-asserted-by":"crossref","unstructured":"8. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003;21:1180\u20139.","DOI":"10.1200\/JCO.2003.10.019"},{"key":"2025120909190349438_j_pp-2016-0002_ref_009_w2aab3b7b9b1b6b1ab2ab9Aa","doi-asserted-by":"crossref","unstructured":"9. Zhao C, Vinh TN, McManus K, Dabbs D, Barner R, Vang R. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol 2009;33:354\u20136.","DOI":"10.1097\/PAS.0b013e318188373d"},{"key":"2025120909190349438_j_pp-2016-0002_ref_010_w2aab3b7b9b1b6b1ab2ac10Aa","doi-asserted-by":"crossref","unstructured":"10. Kommoss F, Schmidt D. Immunohistochemical sex cord markers. Description and use in the differential diagnosis of ovarian tumors. Pathologe 2007;28(3):187\u201394.","DOI":"10.1007\/s00292-007-0912-z"},{"key":"2025120909190349438_j_pp-2016-0002_ref_011_w2aab3b7b9b1b6b1ab2ac11Aa","doi-asserted-by":"crossref","unstructured":"11. Kommoss S, Gilks CB, Penzel R, Herpel E, Mackenzie R, Huntsman D, et al. A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. Histopathology 2014;64(3):380\u20138.","DOI":"10.1111\/his.12253"},{"key":"2025120909190349438_j_pp-2016-0002_ref_012_w2aab3b7b9b1b6b1ab2ac12Aa","unstructured":"12. Sehouli J, Drescher FS, Mustea A, Elling D, Friedmann W, K\u00fchn W, et al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 2004;24(2C):1223\u20139."},{"key":"2025120909190349438_j_pp-2016-0002_ref_013_w2aab3b7b9b1b6b1ab2ac13Aa","doi-asserted-by":"crossref","unstructured":"13. Auranen A, Sundstr\u00f6m J, Ij\u00e4s J, Gr\u00e9nman S. Prognostic factors of ovarian granulosa cell tumor: A study of 35 patients and review of the literature. Int J Gynecol Cancer 2007;17(5):1011\u20138.","DOI":"10.1111\/j.1525-1438.2007.00914.x"},{"key":"2025120909190349438_j_pp-2016-0002_ref_014_w2aab3b7b9b1b6b1ab2ac14Aa","doi-asserted-by":"crossref","unstructured":"14. Ud Din N, Kayani N. Recurrence of adult granulosa cell tumor of the ovary: Experience at a tertiary care center. Ann Diagn Pathol 2014;18(3):125\u20138.","DOI":"10.1016\/j.anndiagpath.2014.02.002"},{"key":"2025120909190349438_j_pp-2016-0002_ref_015_w2aab3b7b9b1b6b1ab2ac15Aa","doi-asserted-by":"crossref","unstructured":"15. Wilson MK, Fong P, Mesnage S, Chrystal K, Shelling A, Payne K, et al. Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up. Gynecol Oncol 2015;138(2):285\u201391.","DOI":"10.1016\/j.ygyno.2015.05.011"},{"key":"2025120909190349438_j_pp-2016-0002_ref_016_w2aab3b7b9b1b6b1ab2ac16Aa","doi-asserted-by":"crossref","unstructured":"16. Staibano S, Franco R, Mezza E, Chieffi P, Sinisi A, Pasquali D, et al. Loss of oestrogen receptor beta, high PCNA and p53 expression and aneuploidy as markers of worse prognosis in ovarian granulosa cell tumours. Histopathology 2003;43(3):254\u201362.","DOI":"10.1046\/j.1365-2559.2003.01706.x"},{"key":"2025120909190349438_j_pp-2016-0002_ref_017_w2aab3b7b9b1b6b1ab2ac17Aa","unstructured":"17. Gurumurthy M, Bryant A, Shanbhag S. Effectiveness of different treatment modalities for the management of adult-onset granulosa cell tumours of the ovary (primary and recurrent). Cochrane Database Syst Rev 2014;4:CD006912."},{"key":"2025120909190349438_j_pp-2016-0002_ref_018_w2aab3b7b9b1b6b1ab2ac18Aa","doi-asserted-by":"crossref","unstructured":"18. van Meurs HS, Buist MR, Westermann AM, Sonke GS, Kenter GG, van der Velden J. Effectiveness of chemotherapy in measurable granulosa cell tumors: A retrospective study and review of literature. Int J Gynecol Cancer 2014;24(3):496\u2013505.","DOI":"10.1097\/IGC.0000000000000077"},{"key":"2025120909190349438_j_pp-2016-0002_ref_019_w2aab3b7b9b1b6b1ab2ac19Aa","doi-asserted-by":"crossref","unstructured":"19. van Meurs HS, van Lonkhuijzen LR, Limpens J, van der Velden J, Buist MR. Hormone therapy in ovarian granulosa cell tumors: A systematic review. Gynecol Oncol 2014;134(1):196\u2013205.","DOI":"10.1016\/j.ygyno.2014.03.573"},{"key":"2025120909190349438_j_pp-2016-0002_ref_020_w2aab3b7b9b1b6b1ab2ac20Aa","unstructured":"20. Oseledchyk A, Zivanovic O. Intraoperative hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer. Oncology (Williston Park) 2015;29(9):695\u2013701."},{"key":"2025120909190349438_j_pp-2016-0002_ref_021_w2aab3b7b9b1b6b1ab2ac21Aa","doi-asserted-by":"crossref","unstructured":"21. Ansaloni L, Coccolini F, Morosi L, Ballerini A, Ceresoli M, Grosso G, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer 2015;112(2):306\u201312.","DOI":"10.1038\/bjc.2014.602"},{"key":"2025120909190349438_j_pp-2016-0002_ref_022_w2aab3b7b9b1b6b1ab2ac22Aa","doi-asserted-by":"crossref","unstructured":"22. Teicher BA, Pfeffer MR, Alvarez Sotomayor E, Herman TS. Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation. Int J Hyperthermia 1991;7(5):773\u201384.","DOI":"10.3109\/02656739109056446"},{"key":"2025120909190349438_j_pp-2016-0002_ref_023_w2aab3b7b9b1b6b1ab2ac23Aa","doi-asserted-by":"crossref","unstructured":"23. Voron T, Eveno C, Jouvin I, Beaugerie A, Lo Dico R, Dagois S, et al. Cytoreductive surgery with a hyperthermic intraperitoneal chemotherapy program: Safe after 40 cases, but only controlled after 140 cases. Eur J Surg Oncol 2015;41(12):1671\u20137.","DOI":"10.1016\/j.ejso.2015.09.005"},{"key":"2025120909190349438_j_pp-2016-0002_ref_024_w2aab3b7b9b1b6b1ab2ac24Aa","doi-asserted-by":"crossref","unstructured":"24. Al-Badawi IA, Abu-Zaid A, Azzam A, AlOmar O, AlHusaini H, Amin T. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of recurrent\/relapsed ovarian granulosa cell tumor: A single-center experience. J Obstet Gynaecol Res 2014;40(9):2066\u201375.","DOI":"10.1111\/jog.12460"},{"key":"2025120909190349438_j_pp-2016-0002_ref_025_w2aab3b7b9b1b6b1ab2ac25Aa","doi-asserted-by":"crossref","unstructured":"25. Gouy S, Uzan C, Pautier P, Lhomme C, Duvillard P, Morice P. Results of oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent ovarian granulosa cell tumors. Eur J Obstet Gynecol Reprod Biol 2013;170(2):464\u20137.","DOI":"10.1016\/j.ejogrb.2013.06.041"},{"key":"2025120909190349438_j_pp-2016-0002_ref_026_w2aab3b7b9b1b6b1ab2ac26Aa","unstructured":"26. Canbay E, Ishibashi H, Sako S, Miyata R, Nishino E, Yonemura Y. Management of peritoneal dissemination of recurrences granulosa cell tumor of the ovary. Gan To Kagaku Ryoho 2012;39(12):2435\u20137."},{"key":"2025120909190349438_j_pp-2016-0002_ref_027_w2aab3b7b9b1b6b1ab2ac27Aa","unstructured":"27. Hayes-Jordan A, Lopez C, Green HL, Xiao LC, Huh W, Herzog CE. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: a novel treatment approach. Pediatr Surg Int. 2015 Oct 25. [Epub ahead of print]"},{"key":"2025120909190349438_j_pp-2016-0002_ref_028_w2aab3b7b9b1b6b1ab2ac28Aa","unstructured":"28. Dogan A, Hilal Z, Cetin C, Tempfer CB. Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy for recurrent adult granulosa cell tumor: A case report. Anticancer Res [in press]."},{"key":"2025120909190349438_j_pp-2016-0002_ref_029_w2aab3b7b9b1b6b1ab2ac29Aa","doi-asserted-by":"crossref","unstructured":"29. Wang PH, Sun HD, Lin H, Wang KL, Liou WS, Hung YC, et al. Outcome of patients with recurrent adult-type granulosa cell tumors \u2013 a Taiwanese gynecologic oncology group study. Taiwan J Obstet Gynecol 2015;54(3):253\u20139.","DOI":"10.1016\/j.tjog.2014.12.007"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/1\/1\/article-p15.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0002\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0002\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:30:35Z","timestamp":1765272635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0002\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,4,12]]},"published-print":{"date-parts":[[2016,3,1]]}},"alternative-id":["10.1515\/pp-2016-0002"],"URL":"https:\/\/doi.org\/10.1515\/pp-2016-0002","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,1]]}}}